[1] Cruz LIB, Lopes LFF, de Camargo Ribeiro F, et al. Anti-Candida albicans activity of thiazolylhydrazone derivatives in invertebrate and murine models[J]. J Fungi (Basel), 2018, 4(4):E134.
[2] Kavanagh K, Sheehan G. The use of Galleria mellonella larvae to identify novel antimicrobial agents against fungal species of medical interest[J]. J Fungi (Basel), 2018, 4(3):E113
[3] Pereira TC, de Barros PP, Fugisaki LRO, et al. Recent advances in the use of Galleria mellonella model to study immune responses against human pathogens[J]. J Fungi (Basel), 2018, 4(4):pii:E128.
[4] Sheehan G, Kavanagh K. Analysis of the early cellular and humoral responses of Galleria mellonella larvae to infection by Candida albicans[J]. Virulence, 2017, 9(1):163-172.
[5] Scorzoni L, de Lucas MP, Mesa-Arango AC, et al. Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile[J]. PLoS ONE, 2013, 8(3):e60047.
[6] Ames L, Duxbury S, Pawlowska B, et al. Galleria mellonella as a host model to study Candida glabrata virulence and antifungal efficacy[J]. Virulence, 2017, 8(8):1909-1917.
[7] Gago S, García-Rodas R, Cuesta I, et al. Candida parapsilosis,Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella[J]. Virulence, 2013, 5(2):278-285.
[8] Mesa-Arango AC, Forastiero A, Bernal-Martínez L, et al. The non-mammalian host Galleria mellonella can be used to study the virulence of the fungal pathogen Candida tropicalis and the efficacy of antifungal drugs during infection by this pathogenic yeast[J]. Med Mycol, 2013, 51(5):461-472.
[9] Garcia-Rodas R, Casadevall A, Rodriguez-Tudela JL, et al. Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection[J]. PLoS One, 2011, 6(9):e24485.
[10] Rossi S A, Trevijano-Contador N, Scorzoni L, et al. Impact of resistance to fluconazole on virulence and morphological aspects of Cryptococcus neoformans and Cryptococcus gattii isolates[J]. Front Microbiol, 2016, 7:153.
[11] Sheehan G, Clarke G, Kavanagh K. Characterisation of the cellular and proteomic response of Galleria mellonella larvae to the development of invasive aspergillosis[J]. BMC Microbiol, 2018, 18(1):63.
[12] Renwick J, Daly P, Reeves EP, et al. Susceptibility of larvae of Galleria mellonella to infection by Aspergillus fumigatus is dependent upon stage of conidial germination[J]. Mycopathologia, 2006, 161(6):377-384.
[13] Gomez-Lopez A, Forastiero A, Cendejas-Bueno E, et al. An invertebrate model to evaluate virulence in Aspergillus fumigatus:the role of azole resistance[J]. Med Mycol, 2014, 52(3):311-319.
[14] Zdybicka-Barabas A, Sowa-Jasi?ek A, St?czek S, et al. Different forms of apolipophorin III in Galleria mellonella larvae challenged with bacteria and fungi[J]. Peptides, 2015, 68:105-112.
[15] Scorzoni L, de Paula e Silva AC, Singulani JdeL, et al. Comparison of virulence between Paracoccidioides brasiliensis and Paracoccidioides lutzii using Galleria mellonella as a host model[J]. Virulence, 2015, 6(8):766-776.
[16] Torres MP, Entwistle F, Coote PJ. Effective immunosuppression with dexamethasone phosphate in the Galleria mellonella larva infection model resulting in enhanced virulence of Escherichia coli and Klebsiella pneumoniae[J]. Med Microbiol and Immunol, 2016, 205(4):333-343.
[17] Clavijo-Giraldo DM, Matinez-Alvarez JA, Lopes-Bezerra LM, et al. Analysis of Sporothrix schenckii sensu stricto and Sporothrix brasiliensis virulence in Galleria mellonella[J]. J Microbiol Methods, 2016, 122:73-77.
[18] Maurer E, Hortnagl C, Lackner M, et al. Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment[J]. Med Mycol, 2019, 57(3):351-362.
[19] Velagapudi R, Hsueh YP, Geunes-Boyer S, et al. Spores as infectious propagules of Cryptococcus neoformans[J]. Infect and Immun, 2009, 77(10):4345-4355.
[20] St. Leger RJ, Screen SE, Shams-Pirzadeh B. Lack of host specialization in Aspergillus flavus[J]. Appl Environ Microbiol, 2000, 66(1):320-324.
[21] Brennan M, Thomas DY, Whiteway M, et al. Correlation between virulence of Candida albicans mutants in mice and Galleria mellonella larvae[J]. FEMS Immunol Med Microbiol, 2002, 34(2):153-157.
[22] Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species[J]. mSphere, 2016, 1(4):e00189-16.
[23] Macedo D, Leonardelli F, Dudiuk C, et al. In vitro and in vivo evaluation of voriconazole-containing antifungal combinations against Mucorales using a Galleria mellonella model of mucormycosis[J]. J Fungi (Basel), 2019, 5(1):E5.
[24] Gu W, Yu Q, Yu C, et al. In vivo activity of fluconazole/tetracycline combinations in Galleria mellonella with resistant Candida albicans infection[J]. J Glob Antimicrob Resist, 2018, 13:74-80.
[25] Sangalli-Leite F, Scorzoni L, Alves de Paula AC, et al. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation[J]. Int J Antimicrob Agents, 2016, 48(5):504-511.
[26] Champion OL, Titball RW, Bates S. Standardization of G. mellonella larvae to provide reliable and reproducible results in the study of fungal pathogens[J]. J Fungi (Basel), 2018, 4(3):E108.